Israeli Researchers Develop New ALS Treatment
JNS.org – Researchers at Israel’s Ben-Gurion University of the Negev (BGU) announced the development of a new treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
The lethal neurodegenerative disorder causes deterioration in the
brain and spinal cord’s motor nerve cells, leading to atrophy, paralysis and eventually death caused by a complete breakdown of the respiratory muscles.
BGU researcher Dr. Rachel Lichtenstein has developed a new method for slowing the advancement of ALS by successfully redesigning a segment of FDA-approved drug MabThera — used to treat autoimmune diseases and certain types of cancer — into a new molecule for treating ALS.
Read More: Algemenier